Vinicius Ernani, M.D.

ErnaniPPVinicius Ernani, M.D.
Assistant Professor, Internal Medicine
Division of Oncology & Hematology

Academic office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840

Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fax. 402-559-6520

Practice locations:
Fred & Pamela Buffett Cancer Center
505 South 45th Street
Omaha, NE 68105 (map)

Nebraska Medicine Village Pointe
111 North 175th Street
Omaha, NE 68118 (map)

Education:
Hematology/Oncology Fellowship: Emory University, Atlanta, GA (2016)
Internal Medicine Residency: University of Miami, Miami, FL (2013)
M.D: Pontificia Universidade Catolica do Rio Grande do Sul, Brazil (2008)

Hospital Appointments:
Nebraska Medicine

Interests:
Novel therapies/clinical trials in lung and head/neck cancers.

Biographical Sketch:
Dr. Ernani is an Assistant Professor in the Department of Hematology/Oncology at the Fred and Pamella Buffett Cancer Center (FPBCC). He received his medical degree in Brazil, and completed his internal medicine residency at the University of Miami. He then went to Emory University in Atlanta, where he completed his hematology and medical oncology fellowship. He joined the faculty at UNMC in 2016. Dr. Ernani has focused his research on lung and head/neck cancers.

Select Publications:
The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. Ernani V, Steuer CE, Jahanzeb M. Annu Rev Med. 2016 Sep 7.

Systemic treatment and management approaches for medullary thyroid cancer. Ernani V, Kumar M, Chen AY, Owonikoko TK. Cancer Treat Rev. 2016 Sep 10;50:89-98. doi: 10.1016/j.ctrv.2016.09.006 Review.

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Kumar M, Ernani V, Owonikoko TK. Mol Aspects Med. 2015 Nov;45:55-66. doi: 10.1016/j.mam.2015.06.009. Review.

Oral Cavity Cancer: Risk Factors, Pathology, and Management. Ernani V, Saba NF. Oncology. 2015;89(4):187-95. doi: 10.1159/000398801. Review.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199.

Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. Paes FM, Ernani V, Hosein P, Serafini AN. J Support Oncol. 2011 Nov-Dec;9(6):197-205. doi: 10.1016/j.suponc.2011.06.004. Review.

Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed